UNSPSC 51111657: Tezacitabine

This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C10H12FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7607Y95N9S, chemically known as mdl 101,731 but generally known as tezacitabine, which bears US NIH Compound Identifier 6435808. The term TEZACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule tezacitabine under HS 29349990 and SITC 51579.

As of Q4 2014, TEZACITABINE remains the US FDA Preferred Term for this commodity. Tezacitabine bears US NLM identifiers UMLS ID C0253087 and NCI Concept Code C1539. SMILES: C1=CN(C(=O)N=C1N)C2C(=CF)C(C(O2)CO)O.

UNSPSC 51111657 Tezacitabine, a Commodity code, represents pharmaceutical products solicited by state health agencies for inclusion in pharmacy benefit programs and direct-to-manufacturer prescription initiatives. State and local governments buy tezacitabine and related oncology pharmaceuticals through health and human services departments managing state employee health plans, Medicaid programs, and specialty pharmacy networks. The Texas Health and Human Services Commission represents the primary recent issuing body under this code, soliciting vendor capabilities for direct manufacturer relationships that bypass traditional pharmacy benefit manager and group purchasing organization channels.

The code shows limited recent activity in the available record. Texas is the only state represented in current solicitations. The Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor information on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI requests vendor experience with direct contracting for self-insured employers and health plans within the past two years, capability to negotiate net pricing models without rebates, and flexibility to implement value-based or outcomes-based agreements. This is a preliminary information-gathering solicitation; no formal evaluation criteria, award values, or budget ranges are identified. The state intends to use vendor responses to develop detailed procurement specifications and pricing models for subsequent formal solicitations.